Free Trial
NASDAQ:CTOR

Citius Oncology (CTOR) Stock Price, News & Analysis

Citius Oncology logo
$1.91 +0.03 (+1.38%)
As of 02:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Citius Oncology Stock (NASDAQ:CTOR)

Advanced

Key Stats

Today's Range
$1.83
$1.95
50-Day Range
$1.61
$2.21
52-Week Range
$0.55
$6.19
Volume
122,156 shs
Average Volume
1.12 million shs
Market Capitalization
$159.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
Consensus Rating
Buy

Company Overview

Citius Oncology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
63rd Percentile Overall Score

CTOR MarketRank™: 

Citius Oncology scored higher than 63% of companies evaluated by MarketBeat, and ranked 381st out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Citius Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Upside Potential

    Citius Oncology has a consensus price target of $6.00, representing about 214.3% upside from its current price of $1.91.

  • Amount of Analyst Coverage

    Citius Oncology has only been the subject of 2 research reports in the past 90 days.

  • Read more about Citius Oncology's stock forecast and price target.
  • Price to Book Value per Share Ratio

    Citius Oncology has a P/B Ratio of 2.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.23% of the float of Citius Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Citius Oncology has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Citius Oncology has recently decreased by 55.24%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Citius Oncology does not currently pay a dividend.

  • Dividend Growth

    Citius Oncology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.23% of the float of Citius Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Citius Oncology has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Citius Oncology has recently decreased by 55.24%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Citius Oncology has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Citius Oncology this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for CTOR on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Citius Oncology to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Citius Oncology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.57% of the stock of Citius Oncology is held by insiders.

  • Percentage Held by Institutions

    70.52% of the stock of Citius Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Citius Oncology's insider trading history.
Receive CTOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Citius Oncology and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CTOR Stock News Headlines

RIP USA
"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fund firm manager who predicted 2008 and 2020 just issued. He says if you're over 50, there's one urgent move you need to make to survive... or risk getting left behind.tc pixel
Maxim Group Upgrades Citius Oncology (NASDAQ:CTOR) to "Buy"
Maxim Group Upgrades Citius Oncology (CTOR)
See More Headlines

CTOR Stock Analysis - Frequently Asked Questions

Citius Oncology's stock was trading at $1.15 at the beginning of 2025. Since then, CTOR shares have increased by 66.0% and is now trading at $1.9090.

Citius Oncology, Inc. (NASDAQ:CTOR) issued its earnings results on Wednesday, May, 14th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.02.

Shares of CTOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Citius Oncology investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Advanced Micro Devices (AMD), Broadcom (AVGO), Confluent (CFLT), Genius Sports (GENI) and Intel (INTC).

Company Calendar

Last Earnings
5/14/2025
Today
10/03/2025
Fiscal Year End
9/30/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CTOR
Previous Symbol
NASDAQ:CTOR
CIK
1851484
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

High Price Target
$6.00
Low Price Target
$6.00
Potential Upside/Downside
+216.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-51.93%
Return on Assets
-22.17%

Debt

Debt-to-Equity Ratio
0.12
Current Ratio
0.35
Quick Ratio
0.02

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.64 per share
Price / Book
2.96

Miscellaneous

Outstanding Shares
83,510,000
Free Float
79,696,000
Market Cap
$158.25 million
Optionable
N/A
Beta
2.92
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:CTOR) was last updated on 10/3/2025 by MarketBeat.com Staff
From Our Partners